<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067028</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0181</org_study_id>
    <nct_id>NCT00067028</nct_id>
  </id_info>
  <brief_title>Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)</brief_title>
  <official_title>A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(&gt;/= 10% Blasts); or CML in Myeloid Blasts Phase as Front Line Therapy or in First Salvage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C,&#xD;
      and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia,&#xD;
      high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed&#xD;
      following their initial therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clofarabine is a new drug that was designed to help treat leukemia. Ara-C and idarubicin are&#xD;
      drugs that are commonly used to help treat leukemia.&#xD;
&#xD;
      Before treatment starts, you will be asked questions about your medical history and have a&#xD;
      complete physical exam. You will have blood samples (about 1 tablespoon) collected for&#xD;
      routine lab tests. You will either have an echocardiogram or a multiple-gated acquisition&#xD;
      (MUGA) scan to check on the function of your heart. You will have a sample of bone marrow&#xD;
      collected to check on the status of the disease. To collect a bone marrow sample, an area of&#xD;
      the hip or chest bone is numbed with anesthetic and a small amount of bone marrow is&#xD;
      withdrawn through a large needle. Women who are able to have children must have a negative&#xD;
      blood or urine pregnancy test.&#xD;
&#xD;
      After each cycle of therapy, you will not receive the next cycle of chemotherapy until your&#xD;
      blood counts have recovered and any possible side effects have gone away (for around 3 to 6&#xD;
      weeks). If the disease gets worse or side effects become too severe, treatment will stop. You&#xD;
      must stay in Houston for the first 4 to 6 weeks (average) of treatment and are required to&#xD;
      return to Houston to receive each additional cycle of chemotherapy (up to 6 days each cycle).&#xD;
&#xD;
      You will be assigned to receive treatment with clofarabine plus idarubicin and ara-C.&#xD;
&#xD;
      For participants in the clofarabine/idarubicin/ara-C group, the clofarabine will be given by&#xD;
      vein over 1 hour once a day for 5 days in a row, on Days 2 to 6 of each cycle. Idarubicin&#xD;
      will be given by vein over 30 minutes for 3 days in a row, on Days 1 to 3 of each cycle.&#xD;
      Ara-C will be given by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.&#xD;
      Idarubicin is usually started around 1 hour after the completion of clofarabine, and ara-C&#xD;
      about 4 hours after the start of the clofarabine infusion. This 6 day period is called a&#xD;
      cycle of chemotherapy.&#xD;
&#xD;
      You will receive at least 1 cycle of therapy. If after 1 or 2 cycles of therapy it is found&#xD;
      that the disease is responding to therapy, you may continue to receive therapy for up to 4&#xD;
      additional courses of &quot;consolidation therapy&quot;. During the &quot;consolidation therapy&quot; you will&#xD;
      also be given treatment courses with ara-C alone. When ara-C is given alone it will be given&#xD;
      as a continuous infusion, 24 hours a day, for 5 days in a row. You will be given a portable&#xD;
      pump so that this treatment can be done as an outpatient. The combination drug courses and&#xD;
      the ara-C courses will alternate (ara-C alone, combination, ara-C alone, combination) for a&#xD;
      total of 4 courses. If it is found that the disease is not responding to chemotherapy, you&#xD;
      will be taken off the study and your doctor will discuss other treatment options with you.&#xD;
&#xD;
      Before you receive each dose of drug(s), you will have a complete physical exam. During&#xD;
      treatment, you will have blood (about 1 tablespoon) collected at least once a week during the&#xD;
      first 2 courses of therapy, then every 2-4 weeks after. Bone marrow samples will be collected&#xD;
      every other week during treatment to check on the status of the disease. The blood and bone&#xD;
      marrow samples may be collected more often if your doctor feels it is necessary.&#xD;
&#xD;
      If, at any time, the disease gets worse or you experience any intolerable side effects, you&#xD;
      will be taken off the study and your doctor will discuss other treatment options with you.&#xD;
&#xD;
      After your last course of treatment, you will have a follow-up visit scheduled. At this&#xD;
      visit, you will have blood (about 1 tablespoon) collected for routine tests. You will have a&#xD;
      sample of bone marrow collected to check on the status of the disease. You will also have a&#xD;
      repeat echocardiogram or MUGA scan to check on the function of your heart.&#xD;
&#xD;
      This is an investigational study. Clofarabine has been authorized by the FDA to be used in&#xD;
      research only. Idarubicin and ara-C are both FDA approved and are commercially available. Up&#xD;
      to 120 participants will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With a Response</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Percentage of participants with complete response following treatment out of all participants in that particular treatment group. Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Clofarabine + Ara-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C Starting dose: 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clofarabine + Idarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clofarabine + Idarubicin + Ara-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine 40mg/m^2</intervention_name>
    <description>40 mg/m^2 by vein over 1 hour daily for 5 days.</description>
    <arm_group_label>Clofarabine + Ara-C</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin 10mg/m^2</intervention_name>
    <description>10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Clofarabine + Idarubicin plus Ara-C:&#xD;
6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
    <arm_group_label>Clofarabine + Idarubicin</arm_group_label>
    <other_name>Idamycin®,</other_name>
    <other_name>Idamycin PFS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C 0.75 g/m^2</intervention_name>
    <description>0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
    <arm_group_label>Clofarabine + Idarubicin + Ara-C</arm_group_label>
    <other_name>Cytosar-U®</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine 22.5mg/m^2</intervention_name>
    <description>22.5 mg/m^2 by vein over 1 hour daily for 5 days.</description>
    <arm_group_label>Clofarabine + Idarubicin</arm_group_label>
    <arm_group_label>Clofarabine + Idarubicin + Ara-C</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C 1 g/m^2</intervention_name>
    <description>1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
    <arm_group_label>Clofarabine + Ara-C</arm_group_label>
    <other_name>Cytosar-U®</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin 6 mg/m^2</intervention_name>
    <description>6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
    <arm_group_label>Clofarabine + Idarubicin + Ara-C</arm_group_label>
    <other_name>Idamycin®,</other_name>
    <other_name>Idamycin PFS®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/= 18 years and &lt; 60 years.&#xD;
&#xD;
          2. Must be in first relapse of AML, or must receive treatment as first salvage in primary&#xD;
             refractory AML; or have high-risk MDS (&gt;/= 10% blasts) with not more than one prior&#xD;
             regimen of chemotherapy (therapy with hematopoietic growth factors, biological or&#xD;
             targeted therapies are not counted). Patients in CML myeloid blast phase may receive&#xD;
             clofarabine as frontline therapy or in first salvage.&#xD;
&#xD;
          3. Total bilirubin &lt;/= 2mg/dL, Serum glutamic pyruvic transaminase (SGPT) &lt;/= 4 upper&#xD;
             limit of normal (ULN), creatinine &lt;/= 2.0mg/dL.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2.&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
          6. Male and female patients who are fertile agree to use an effective barrier method of&#xD;
             birth control (ie, latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.&#xD;
             Female patients need a negative serum or urine pregnancy test within 7 days of study&#xD;
             enrollment (applies only if patient is of childbearing potential. Non-childbearing is&#xD;
             defined as &gt;= 1 year postmenopausal or surgically sterilized).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with clofarabine.&#xD;
&#xD;
          2. Active, uncontrolled, systemic infection considered opportunistic, life threatening,&#xD;
             or clinically significant at the time of treatment, or any severe, concurrent disease,&#xD;
             which, in the judgment of the investigator and after discussion with the Principal&#xD;
             Investigator, would make the patient inappropriate for study entry.&#xD;
&#xD;
          3. Symptomatic central nervous system (CNS) involvement.&#xD;
&#xD;
          4. Patients who receive other chemotherapy. Patients must have been off previous therapy&#xD;
             of &gt;/= 2 weeks and must have recovered from acute toxicity of all previous therapy&#xD;
             prior to enrollment. Treatment may start earlier following discussion with the&#xD;
             Principal Investigator.&#xD;
&#xD;
          5. Cardiac ejection fraction &lt;/= 30%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan H Faderl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 8, 2003</study_first_submitted>
  <study_first_submitted_qc>August 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2003</study_first_posted>
  <results_first_submitted>November 11, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>CML Myeloid Blast Phase</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Clofarex</keyword>
  <keyword>Clolar</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Idarubicin</keyword>
  <keyword>Idamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 2003 to October 2009. All participants were recruited at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clofarabine + Ara-C</title>
          <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C :1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
        <group group_id="P2">
          <title>Clofarabine + Idarubicin</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Clofarabine + Idarubicin + Ara-C</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clofarabine + Ara-C</title>
          <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C : 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
        <group group_id="B2">
          <title>Clofarabine + Idarubicin</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Clofarabine + Idarubicin + Ara-C</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="39" upper_limit="73"/>
                    <measurement group_id="B2" value="57" lower_limit="25" upper_limit="73"/>
                    <measurement group_id="B3" value="51" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="B4" value="54" lower_limit="18" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With a Response</title>
        <description>Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>Two participants in the Clofarabine + Idarubicin (CI) arm were not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine + Ara-C</title>
            <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C : 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
          </group>
          <group group_id="O2">
            <title>Clofarabine + Idarubicin</title>
            <description>Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine + Idarubicin + Ara-C</title>
            <description>Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Response</title>
          <description>Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
          <population>Two participants in the Clofarabine + Idarubicin (CI) arm were not evaluable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Percentage of participants with complete response following treatment out of all participants in that particular treatment group. Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine + Ara-C</title>
            <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C : 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
          </group>
          <group group_id="O2">
            <title>Clofarabine + Idarubicin</title>
            <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Clofarabine + Idarubicin + Ara-C</title>
            <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Percentage of participants with complete response following treatment out of all participants in that particular treatment group. Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count &gt; 1.0 x10^9/L and platelet count &gt;100x10^9/L, and normal bone marrow differential (&lt; 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of &gt; 20 x 10^9/L and &lt; 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of &gt; 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clofarabine + Ara-C</title>
          <description>Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Ara-C :1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
        <group group_id="E2">
          <title>Clofarabine + Idarubicin</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Clofarabine + Idarubicin + Ara-C</title>
          <description>Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.&#xD;
Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.&#xD;
Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Prolonged Myelosuppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholevystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Infection (orbit)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Infection (Skin Abcess)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="47" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="69" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" events="78" subjects_affected="63" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="50" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" events="66" subjects_affected="63" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="36"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="36"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Anorexia/Dyspepsia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CNS</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="77" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="52" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" events="68" subjects_affected="63" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="59" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" events="63" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hagop M Kantarjian,MD/Chair, Leukemia</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>(713) 792-7026</phone>
      <email>hkantarjian@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

